Hengrui Medicine gets green light for HRS-5635 trial

Jiangsu Hengrui Medicine Co., Ltd. [SSE:600276] announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for clinical trials of HRS-5635 injection. This drug, a new generation liver-targeted siRNA drug for hepatitis B virus (HBV), will undergo clinical trials to assess its efficacy in combination with Peg-IFNa for chronic hepatitis B treatment. Preclinical studies have demonstrated HRS-5635's potent antiviral activity against all HBV genotypes and a favorable safety profile. As of now, there are no similar drugs approved globally. Hengrui Medicine has invested approximately CNY 13,028 million in the research and development of HRS-5635 to date. The company cautioned that the drug's path to market involves uncertainties and will actively advance the project while fulfilling its disclosure obligations.